Third stage ovarian carcinoma - case report: the necessity of a multidisciplinary approach to treatment

Ovarian carcinoma, part of a heterogeneous group of tumours, is the main cause of death by gynaecological neoplasms. The diagnosis, in general, is delayed. Multiorgan diffusion, the necessity of a surgical operation and strong chemotherapy, and the eventual pathology due to patient age are all factors that require a multidisciplinary approach. In fact the case, here reported, refers to a patient who came under our observation for a bilateral ovarian mass discovered casually during an abdominal ultrasound exam carried out for renal colic. Excellent cytoreduction with peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy (Figure 2), bilateral pelvic lymphadenectomy, total omentectomy, removal of nodules from the mesentery, the colon and three nodules in the abdominal wall thickness was executed. The histological report was G3, angioinvasive bilateral ovarian endometrioid adenocarcinoma. Metastasis was found only in one left obturator lymph node out of 17 lymph nodes removed. All of the removed abdominal, mesenteric and intestinal nodules were neoplastic. It is concluded that the complexity of similar cases always requires a multidisciplinary approach as in our case, involving an oncologist, hematologist, surgeon, gynaecologist, radiologist, anaesthesiologist, and nursing staff in the management of third stage ovarian cancer patients to obtain the best treatment thus guaranteeing a higher survival rate and better quality of life.

Ovarian carcinoma; Gynaecological neoplasm; Chemotherapy

[1] Benedet J.L., Haker N.F., Ngan H.Y.S.: "Staging classifications and clinical practice guidelines of gynaecologic cancers". Int. J Gynecol. Obstet., 2000, 70, 207.

[2] Hoskins W.J.: "Surgical staging and cytoreductive surgery of epithelial ovarian cancer". Cancer, 1993, 71, 1534.

[3] GoffB.A., Mandel L.S., Melancon C.H., Muntz H.G.: "Frequency of symptoms of ovarian cancer in women presenting to primary care clinics". JAMA, 2004, 291, 2705.

[4] Forstner R., Hricak H., Occhipinti K.A., Powell C.B., Frankel S.D., Stern J.L.: "Ovarian cancer: staging with CT and MR imaging". Radiology, 1995, 197, 619.

[5] Schutter E.M.J., Davelaar E.M., van Kamp G.J., Verstraeten R.A., Kenemans P., Verheijen R.H.M.: "The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass". Am. J. Obstet. Gynecol., 2002, 187, 385.

[6] Griffiths C.T., Parker L.M., Lee S., Finkler N.J.:'The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results". Int. J. Gynecol. Cancer, 2002, 12, 323.

[7] Saia P., Creasman W.: "Epithelial ovarian cancer". Clinical Gynecologic Oncology. 6'h ed山on, N.Y., Mosby, 289, 2002.

[8] Maggioni A., Maneschi F., Mangioni C., Landoni F., Scambia G., et al.: "Randomized trial of lymphadenectomy (LY) vs. sampling (SA) or resection of bulky nodes (RBN) as primari surgical procedure in early epihtelial ovarian cancer". Int. J. Gynecol. Cancer, 1999, 9, 43.

[9] Fioretti P., Gadducci A., Ferdeghini M., Prontera C., Malagnino G., Facchini V. et al.: "The concomitant determination of different serum tumor markers in epithelial ovarian cancer: Relevance for monitoring the response to chemotherapy and follow-up of patients". Gynecol. Oncol., 1992, 44, 155.

[10] Van Dam P.A., DeCloedt J., TjaJma W., Buytaert P., Becquart D., Vergote LB.: "Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: Can the risk be reduced?". Am. J. Obstet. Gynecol., 1999, 181, 536.

[11] Kruitwagen R.F.P.M., Swinkels B.M., Keyser K.G.G., Doesburg W.H., Schijf C.P.T.: "Incidence and effect on survival of abdominal wall metastases at trocar or puncture sites following laparoscopy or paracentesis in women with ovarian cancer". Gynecol. Oncol., 1996, 60, 233.

[12] Morice P., Viala J., Pautier P., Lhomme C., Duvillard P., Castaigne D.: "Port-site metastasis after laparoscopic surgery for gynecologic cancer. A report of six cases". J. Reprod. Med., 2000, 45, 837.

[13] Carlson N.L., Krivak T.C., Winter W.E., Macrl C.I.: "Port site metastasis of ovarian carcinoma remote from laparoscopic surgery for benign disease". Gynecol. Oncol., 2002, 85, 529.

[14] Leyland-Jones B.: "Breast cancer trial with erythropoietin term1-nated unexpectedly". Lancet Oncol., 2003, 4, 459.

[15] Brower V.: "Epoetin for cancer patients: a boon or a danger?". J Nat. Cancer Inst., 2003, 95, 1820.

[16] Scholz H.S., Lax S., Tamussino K.F., Petru E.: "Inguinal lymph node metastasis as the only manifestation of lymphatic spread in ovarian cancer: A case report". Gynecol. Oncol., 1999, 75, 517.

[17] McGonigle K.F., Dudzinski M.R.: "Endometrioid carcinoma of the ovary presenting with an enlarged inguinal lymphnode without evidence of abdominal carcinomatosis". Gynecol. Oncol., 1992, 45, 225.

[18] Mangioni C., Bonazzi C., Colombo N., Epis A., Landoni F., Vasena L. et al. : "Pathologic complete responses in advanced epithelial ovarian cancer: prognostic factors for long-term survival". In: Conte P.F., Ragni N., Rosso R., Vennorken J.B., eds. Multimodal Treatment of Ovarian Cancer. New York, Raven Press 1989, 271.